Development of experimental pneumococcal vaccine for mucosal immunization

Area of Science:

• Microbiology
• Immunology
• Vaccinology

Background:

• Streptococcus pneumoniae causes severe diseases like pneumonia, otitis, and meningitis.
• Current vaccines are effective but costly and require updates for evolving strains.
• There is a need for new, accessible pneumococcal vaccines.

Purpose of the Study:

• To develop a novel mucosal vaccine candidate against Streptococcus pneumoniae.
• To express pneumococcal antigens on the surface of a live probiotic bacterium for immunization.

Main Methods:

• Chimeric protein PSPF antigens were expressed on the surface of Enterococcus faecium L3.
• Laboratory mice were immunized with the live engineered probiotic bacteria.
• Humoral immune responses (IgA and IgG) were measured post-vaccination.

Main Results:

• Specific IgA and IgG antibodies were detected in vaccinated mice.
• Mice vaccinated with the engineered probiotic showed protection against lethal S. pneumoniae infection.
• This indicates the potential of the live bacterial vector for mucosal immunization.

Conclusions:

• The developed live probiotic Enterococcus faecium L3 expressing S. pneumoniae antigens is a promising mucosal vaccine candidate.
• This approach offers a potential alternative to conventional vaccines for pneumococcal disease prevention.
• Further research is warranted to evaluate its efficacy and safety in human trials.